Cutler Group’s PharmaCyte Biotech PMCB Stock Holding History

Cutler Group’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-78	Closed	-$215	–	5891
2021 Q3	$0	Buy	+78	New	+$274	﹤0.01%	6214

Other funds holding PMCB

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Cutler Group's PMCB Position: Q4 2021 in Review

Cutler Group sold out of PharmaCyte Biotech (PMCB) in Q4 2021, closing a stake of 78 shares — an estimated $215 sold.

Cutler Group first reported a position in PMCB in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 26 funds tracked by Wall St. Rank hold PMCB as of Q4 2021.

Cutler Group reported no remaining PharmaCyte Biotech position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 78 PharmaCyte Biotech shares in Q4 2021, an estimated $215.
Cutler Group first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 1 quarter.
Cutler Group's PharmaCyte Biotech position peaked at $0 in Q3 2021.
26 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.